Literature DB >> 30046577

Potent suppression of hepatitis B virus and hepatocellular carcinoma: how long is good enough?

Sudha Kodali1, Ashwani K Singal1.   

Abstract

Entities:  

Year:  2018        PMID： 30046577      PMCID： PMC6036064          DOI： 10.21037/hbsn.2018.03.07

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  12 in total

1.  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

Authors: 
Journal:  J Hepatol       Date:  2012-03-20       Impact factor: 25.083

Review 2.  Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.

Authors:  George V Papatheodoridis; Pietro Lampertico; Spilios Manolakopoulos; Anna Lok
Journal:  J Hepatol       Date:  2010-04-27       Impact factor: 25.083

3.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

4.  New Direct-Acting Antiviral Agents and Immunomodulators for Hepatitis B Virus Infection.

Authors:  Marion G Peters; Stephen Locarnini
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-06

5.  Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.

Authors:  A K Singal; H Salameh; Y-F Kuo; R J Fontana
Journal:  Aliment Pharmacol Ther       Date:  2013-05-28       Impact factor: 8.171

6.  Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Authors:  Yun-Fan Liaw; Joseph J Y Sung; Wan Cheng Chow; Geoffrey Farrell; Cha-Ze Lee; Hon Yuen; Tawesak Tanwandee; Qi-Min Tao; Kelly Shue; Oliver N Keene; Jonathan S Dixon; D Fraser Gray; Jan Sabbat
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.

Authors:  Tetsuya Hosaka; Fumitaka Suzuki; Masahiro Kobayashi; Yuya Seko; Yusuke Kawamura; Hitomi Sezaki; Norio Akuta; Yoshiyuki Suzuki; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Mariko Kobayashi; Hiromitsu Kumada
Journal:  Hepatology       Date:  2013-03-06       Impact factor: 17.425

8.  The natural history of chronic hepatitis B virus infection.

Authors:  Brian J McMahon
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

9.  AASLD guidelines for treatment of chronic hepatitis B.

Authors:  Norah A Terrault; Natalie H Bzowej; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; M Hassan Murad
Journal:  Hepatology       Date:  2015-11-13       Impact factor: 17.425

10.  PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.

Authors:  George Papatheodoridis; George Dalekos; Vana Sypsa; Cihan Yurdaydin; Maria Buti; John Goulis; Jose Luis Calleja; Heng Chi; Spilios Manolakopoulos; Giampaolo Mangia; Nikolaos Gatselis; Onur Keskin; Savvoula Savvidou; Juan de la Revilla; Bettina E Hansen; Ioannis Vlachogiannakos; Kostantinos Galanis; Ramazan Idilman; Massimo Colombo; Rafael Esteban; Harry L A Janssen; Pietro Lampertico
Journal:  J Hepatol       Date:  2015-12-08       Impact factor: 25.083
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.